Ultragenyx Pharmaceutical and Mereo BioPharma Group saw their shares plummet after ringing out 2025 by announcing the failures of their brittle bone disease candidate setrusumab (UX143) in a pair of ...
People who struggle with imposter syndrome believe that they are undeserving of their achievements and the high esteem in which they are, in fact, generally held. They feel that they aren’t as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback